Table 5.
Safety analyses results using the safety analysis set
| Safety outcome measure | Values | Percentage standardized difference | Estimated differencea | 95% Confidence Intervala | P valuea | |
|---|---|---|---|---|---|---|
| Intervention (GKT137831) group (n = xxx) | Placebo group (n = xxx) | |||||
| Treatment-emergent adverse events, n (%) | ||||||
| Abnormal laboratory analytes, n (%) | ||||||
| Abnormal physical examination and vital signs, n (%) | ||||||
| QT corrected electrocardiogram (ECG), mean (SD) | ||||||
| Treatment-emergent qualitative ECG, n (%) | ||||||
| Concomitant medications, n (%) | ||||||
| Systolic blood pressure (mmHg), mean (SD) | ||||||
| Diastolic blood pressure (mmHg), mean (SD) | ||||||
| Heart rate (beats per minute), mean (SD) | ||||||
| Weight (Kg), mean (SD) | ||||||
SD standard deviation
a If feasible to carry out testing; in the intervention group compared to the placebo group